ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Stonepine Capital Management LLC

Key Points

• Stonepine Capital Management LLC increased its stake in ANI Pharmaceuticals by 135.3%, now holding 48,000 shares valued at approximately $3.21 million, making it the firm's 10th largest investment.
• Insider transactions included significant sales by directors, with Jeanne Thoma selling 21,540 shares for about $1.92 million, representing a 47.93% decrease in her position.
• ANI Pharmaceuticals recently reported a quarterly earnings beat with an EPS of $1.80, surpassing estimates and showing a 53.2% year-over-year revenue growth to $211.37 million.

Stonepine Capital Management LLC grew its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 135.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 48,000 shares of the specialty pharmaceutical company's stock after purchasing an additional 27,600 shares during the period. ANI Pharmaceuticals makes up 3.1% of Stonepine Capital Management LLC's investment portfolio, making the stock its 10th largest position. Stonepine Capital Management LLC owned 0.22% of ANI Pharmaceuticals worth $3,214,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Millennium Management LLC lifted its stake in shares of ANI Pharmaceuticals by 89.3% in the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock valued at $55,437,000 after purchasing an additional 473,097 shares during the last quarter. Global Alpha Capital Management Ltd. lifted its stake in shares of ANI Pharmaceuticals by 17.8% in the 1st quarter. Global Alpha Capital Management Ltd. now owns 735,590 shares of the specialty pharmaceutical company's stock valued at $49,248,000 after purchasing an additional 111,040 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of ANI Pharmaceuticals by 4.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 685,730 shares of the specialty pharmaceutical company's stock valued at $37,906,000 after purchasing an additional 30,420 shares during the last quarter. Deep Track Capital LP lifted its stake in shares of ANI Pharmaceuticals by 28.6% in the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after purchasing an additional 144,214 shares during the last quarter. Finally, Aberdeen Group plc lifted its stake in shares of ANI Pharmaceuticals by 76.1% in the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company's stock valued at $28,059,000 after purchasing an additional 181,134 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

Insiders Place Their Bets

In other news, CEO Nikhil Lalwani sold 56,960 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $85.93, for a total value of $4,894,572.80. Following the transaction, the chief executive officer owned 411,219 shares in the company, valued at approximately $35,336,048.67. This represents a 12.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Chad Gassert sold 20,000 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $86.97, for a total value of $1,739,400.00. Following the completion of the transaction, the senior vice president owned 173,226 shares in the company, valued at approximately $15,065,465.22. The trade was a 10.35% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 405,538 shares of company stock worth $35,690,131. 11.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

ANIP has been the topic of several recent analyst reports. Truist Financial upped their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research note on Monday, August 11th. Guggenheim reiterated a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Zacks Research upgraded ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 21st. Piper Sandler reiterated an "overweight" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, August 8th. Finally, Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $84.75.

ANI Pharmaceuticals Stock Down 0.0%

NASDAQ ANIP traded down $0.01 during trading hours on Wednesday, hitting $91.88. 241,668 shares of the company were exchanged, compared to its average volume of 737,918. The company has a 50 day moving average of $72.27 and a two-hundred day moving average of $66.56. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $92.65. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of 17.88 and a beta of 0.61.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The company had revenue of $211.37 million for the quarter, compared to the consensus estimate of $187.18 million. During the same quarter in the prior year, the business earned $1.02 EPS. ANI Pharmaceuticals's revenue was up 53.2% on a year-over-year basis. Equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.